Phase 1, pharmacogenomic, dose-expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1-deficient non-squamous non-small cell lung cancer.
Peter W SzlosarekAkhila G WimalasinghamMelissa M PhillipsPeter E HallPui Ying ChanJohn ConibearLouise LimSukaina RashidJeremy SteelePaula WellsChiung-Fang ShiuChih-Ling KuoXiaoxing FengAmanda JohnstonJohn BomalaskiStephen EllisMarianne GranthamMichael SheaffPublished in: Cancer medicine (2021)
ADIPemCis was safe and highly active in patients with ASS1-deficient non-squamous NSCLC, however, survival was poor overall. ASS1 loss was co-associated with p53 mutations. Therapies incorporating pegargiminase merit further evaluation in ASS1-deficient and treatment-refractory NSCLC.